<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04993079</url>
  </required_header>
  <id_info>
    <org_study_id>SEN_CLOTILD_FIH_1</org_study_id>
    <nct_id>NCT04993079</nct_id>
  </id_info>
  <brief_title>Clotild® Smart Guidewire System (CSGS) Evaluation in EndovascUlar Thrombectomy Procedure</brief_title>
  <acronym>CLOTOUT</acronym>
  <official_title>Clotild® Smart Guidewire System Evaluation in Endovascular Thrombectomy Procedure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sensome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sensome</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this First-in-Human study is to evaluate the safety of using the Clotild®&#xD;
      system to guide the endovascular thrombectomy (EVT) device to the clot location during EVT&#xD;
      for the treatment of an acute ischemic stroke eligible to EVT, whatever the EVT device&#xD;
      chosen. A secondary purpose is to assess the clinical performance, defined as the feasibility&#xD;
      of measuring clot electrophysiological parameters in vivo during EVT procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clotild® is a neurovascular guidewire equipped with the Sensome proprietary impedance sensor.&#xD;
      The latter allows the measurement of the electrophysiological characteristics of the&#xD;
      surrounding tissues. Clotild® could categorize the thrombus occluding the cerebral blood&#xD;
      vessel, and support the neurointerventionist during mechanical thrombectomy for the treatment&#xD;
      of ischemic stroke. The aim of the study is to evaluate the safety and the performance of the&#xD;
      device. The electrophysiological measurements will be used to update Clotild®'s database and&#xD;
      thus improve the prediction accuracy of the model in providing physicians with insights for&#xD;
      mechanical thrombectomy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients having intracranial vessel perforation and / or dissection due to Clotild® usage at the site of usage in intracranial vessels</measure>
    <time_frame>Measured during the procedure</time_frame>
    <description>Tthe proportion of patients having intracranial vessel perforation and / or dissection due to Clotild® usage at the site of usage in intracranial vessels will be assessed by Interventional Neuroradiologist during the procedure and final adjudication of the DSA (Digital Subtraction Angiography) by the Data Safety Monitoring Board.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The ability to perform binary classification of individual electrophysiological parameter measurements</measure>
    <time_frame>Measured during the procedure</time_frame>
    <description>The ability to perform binary classification of individual electrophysiological parameter measurements will be assessed by distinguishing local regions with substantial red blood cell content (RBC-rich) from regions with negligible red blood cell content (RBC-poor) in the occlusion.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Clotild®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects presenting an acute ischemic stroke due to M1 or middle cerebral artery (MCA) bifurcation occlusion, eligible for Endovascular Thrombectomy (EVT) based on neuro-interventionist and/or neurologist investigators' opinion will be eligible. Twenty (20) patients will be initially enrolled. Up to 100 patients will be enrolled following an analysis of the data of the first 20 enrolled patients by a data safety monitoring board (DSMB) and its' recommendation to proceed with the study.&#xD;
Sixty clots will be retrieved and analysed in a group of participants for which Clotild® is used as neurovascular guidewire.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Clotild®</intervention_name>
    <description>Use of Clotild® as neurovascular guidewire</description>
    <arm_group_label>Clotild®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical signs and symptoms consistent with the diagnosis of an acute ischemic stroke&#xD;
             eligible for EVT&#xD;
&#xD;
          2. M1 and/or MCA bifurcation arterial occlusion on Computed tomography angiography (CTA)&#xD;
             or MRA (Magnetic resonance angiography) of an intracranial vessel amenable to EVT&#xD;
&#xD;
          3. Informed Consent by subject, subject's Legally Authorized Representative (LAR) or&#xD;
             anyone approved by the Ethics Committee (EC) and/or regulatory agencies to provide&#xD;
             consent on behalf of the subject.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient having an intracranial occlusion other than M1 and/or MCA bifurcation,&#xD;
             especially tandem occlusion and ICA (internal carotid artery) occlusion.&#xD;
&#xD;
          2. Current participation in another investigational device or drug study that has not&#xD;
             completed the primary endpoint or that clinically interferes with the current study&#xD;
             endpoints&#xD;
&#xD;
          3. Candidates not eligible for EVT based on neurointerventionist and/or neurologist&#xD;
             investigators' opinion&#xD;
&#xD;
          4. Pregnancy or lactating subjects&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Cheung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liverpool Hospital, Liverpool NSW, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dennis Cordato, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liverpool Hospital, Liverpool NSW, Australia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hans Tielemans</last_name>
    <phone>+33 1 85 37 07 70</phone>
    <email>hans@sensome.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Franz Bozsak</last_name>
    <phone>+33 1 85 37 07 70</phone>
    <email>franz@sensome.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>NSW 2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dennis Cordato</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>QLD 4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alan Coulthard</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gold Coast University Hospital</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>QL 5215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hal Rice</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 1, 2020</study_first_submitted>
  <study_first_submitted_qc>August 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

